FDA D.I.S.C.O. Burst Edition: FDA approval of Brukinsa (zanubrutinib) for adult patients with Waldenström’s macroglobulinemia

Veröffentlicht:

Listen to a soundcast of the August 31, 2021 FDA approval of Brukinsa (zanubrutinib) for adult patients with Waldenström’s macroglobulinemia

FDA D.I.S.C.O. Burst Edition: FDA approval of Brukinsa (zanubrutinib) for adult patients with Waldenström’s macroglobulinemia

Titel
FDA D.I.S.C.O. Burst Edition: FDA approval of Brukinsa (zanubrutinib) for adult patients with Waldenström’s macroglobulinemia
Copyright
Veröffentlicht

flashback